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 Linagliptin is an oral anti-diabetic drug belong to the class of dipeptidyl peptidase -4 (DPP-4 
inhibitors).It is widely used in the treatment of type –II diabetes mellitus which is 
characterized by insulin resistance in pheripheral tissue and insulin secretory defect of the β – 
cells.Linagliptin is been approved by the US food & Drug administration for the management 
of type –II diabetes. This work aims to compiling the published analytical methods referred 
so far in the literature in the determination of linagliptin in the biological samples and 
pharmaceutical formulations. Techniques like HPLC, UV & MASS spectroscopy, EI – 
Tandem Mass spectrometry, pharmacokinetic studies & spectrophotometric methods have 
been utilized so far in the analysis, from which we can seen HPLC methods have been 
operated most extensively in various analytical perspectives. Based on the findings of the 
present review, linagliptin is widely used as an treatment adjunctive to a regimen of an insulin 
secretagogue. 
Please cite this article in press as S. D. Shanmugakumar et al. A Review of Analytical Perspectives of Linagliptin. Indo American 
Journal of Pharmaceutical Research.2017:7(07). 
                                                   
www.iajpr.com 
P
ag
e2
2
6
 
Vol 7, Issue 07, 2017.                                                S. D. Shanmugakumar et al.                                               ISSN NO: 2231-6876 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
Linagliptin { 1 H – ( Purine-2,6 dione, 8- (3R) – 3- amino -1- Piperdinyl) -7 –(2- butyn -1-yl) -3,7 dihydro – 3-methyl – 1 – ( 
4 methyl -2- quinazolinyl) Methyl} is a DPP-4 inhibitors in the treatment of type –II diabetes, DPP-4 (Dipeptidyl pepitadase -4) is an 
enzyme that degrades the hormones, glucagon like peptides -1 (GLP-1)  and glucose dependent insulin tropic polypeptide (GIP).Both 
GLP-1 & GIP increases the insulin biosynthesis and secretion from pancreatic α –Cells resulting in the reduction of hepatic glucose 
output [1].Linagliptin is indictaed as adjuvant to diet and exercise to improve glycemic control in patients with diabetes –II [2]. 
Various techniques have been reported in the determination of linagliptin in the pharmaceutical dosage forms.The objective of review 
article is to understand the various simple accurate RP-HPLC methods with short retention time (migration time) and various methods  
to validate the newly developed method as per the ICH guidelines[3].In the present review, we have  compiled the published analytical 
methods reported so far in the determination of linagliptin in pharmaceutical and biological samples.Techniques like 
spectrophotometry,HPLC,LCMS,LC-ESI-MS where have been used for analysis, from which HPLC methods were been extensively 
adopted. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1 Structure of linagliptin. 
 
 
 
 
 
 
 
 
 
 
 
Fig.2 Overview of analytical methods for estimation of a linagliptin in pharmaceutical and biological samples 
 
Sample preparation strategies  
 Sample preparation is an integral part of analytical methodology and it was reported that approximately 30 % error is 
contributed from sample analysis was due to sample preparation [6]. The various  diluents utilized for analysis of linagliptin are 0.02M 
phosphate buffer (p
H
 5.5), acetonitrile, methanol. In major cases, methanol was used as a diluent. The sample preparation techniques 
for the extraction` of linagliptin from biological matrices like serum, plasma and urine include liquid –liquid extraction with diethyl 
ether, N-butyl ether & ethyl acetate and protein precipitated with methanol. 
 
Analytical methods  
Spectrophotometry: 
 In the literature, twenty simple, accurate, zero order, first derivative spectrophotometric methods have been developed [7] out 
of which  four methods were for determination of linagliptin alone, where as remaining are quantifying linagliptin in combination with 
other drug substances. 
 
Table :1 Representative spectroscopical method analysis of linagliptin. 
 
S.NO Compound Method ƛmax Solvent LOD Reference 
1. Linagliptin Spectrophotometric 299 Methanol 0.247 [8] 
2. Linagliptin Spectrophotometric 294 Methanol & Water 0.246 [9] 
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Chromatography: 
Biological samples: 
 Rutvik H pandya et.al [10] developed a method in human plasma by using simultaneous method for estimation of linagliptin 
and metformin in combined dosage form. The mobile phase used in this method was a mixture of acetonitrile and 0.01 M diphopshate 
buffer adjusting the p
H
 7.0 with orthophosphoric acid ( 75:25v/v). Phenformin was used as a internal standard for this method. The 
method has been validated as per the ICH guide lines such as long term stability studies, LLOQ, LQC,MQC & HQC concentration 
levels were found to be 9.823,1.983,1.325 & 2.715 respectively. 
 
Pharmaceutical samples: 
Analytical methods for the determination of linagliptin in the pharmaceutical dosage form using HPLC [11-20] 
 
Table :2 Reported analytical HPLC methods for determination of linagliptin in combination with other drugs like metformin 
in pharmaceutical dosage forms. 
 
S.No Aim of study Mobile 
phase 
Column Detection ƛ max 
(nm) 
Flow 
rate 
LOD  
µg/mL 
reference 
1. Validated RP-HPLC 
method for the 
determination of linagliptin 
Methanol : 
Water 
(83:17v/v) 
Gemini C18 
column 
(250x4.6mm, 
I.D, 5µm) 
UV 241 1mL/min 2.5 [11] 
2. Simultaneous estimation of 
metformin and linagliptin 
in tablet dosage forms 
Acetonitril
e : 0.2M 
Phosphate 
Buffer 
(35:65 v/v) 
Waters X- 
bridge C18 
column  ( 
4.6X150mm 
ID, 5µm) 
UV 225 1mL/min 2.6 [12] 
3. Simultaneous estimation 
and stability indicating 
study of Metformin and 
linagliptin in dosage forms 
Phosphate 
buffer : 
acetonitrile 
(60:40) 
Inertsil ODS -
3V C18 
column 
(250X4.6mm 
ID, 5µm) 
PDA 280 1mL/min 2.7 [13] 
4. Development and 
validation of stability 
indicating RP-HPLC 
method for the 
simultaneous estimation of 
linagliptin and metformin 
Acetonitril
e : Water : 
Methanol 
(25:20:25 
v/v) 
BDS hypersil 
C8 column 
(250x4.6mm 
ID, 5µm) 
PDA 243 1mL/min 0.89 [14] 
5. Validated RP-HPLC 
method for the 
determination of linagliptin 
Methanol : 
Water 
(83:17 v/v) 
Gemini C18 
column 
(250x4.6mm 
ID, 5µm) 
UV 241 1mL/min 0.025 [15] 
6. Determination of 
Metformin hydrochloride 
and linagliptin by RP-
HPLC in bulk and 
Pharmaceutical formulation 
Phosphate 
buffer : 
Methanol : 
acetonitrile 
(65:10:25v/
v) 
Phenomex 
luna RP-18 
reverse phase 
C18 column 
(150x4.6mm 
ID, 5µm) 
UV 231 1mL/min 3.08 [16] 
7. Stability indicating liquid 
chromatographic method 
for simultaneous assay of 
linagliptin and metformin 
pure and tablet dosage form 
Phosphate 
buffer : 
acetonitrile 
(40:60v/v) 
Zorbax CV18 
column 
(250X4.6mm 
ID, 5µm) 
PDA 236 1mL/min 0.673 [17] 
8. Simultaneous 
determination of linagliptin 
and metformin by RP-
HPLC method 
Methanol : 
0.05M 
potassium 
dihydrogen 
orthophosp
hate 
(70:30v/v) 
Lichrosphere 
100 RP -18e ( 
125x4mm ID, 
5µm) 
PDA 267 0.6mL/m
in 
0.07591 [18] 
9. Simultaneous 
determination of metformin 
Dihydroge
n 
Chromolith 
C18 
UV 208 2.5mL/m
in 
0.02 [19] 
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and 3 gliptins in 
pharmaceutical 
formulations using RP-
HPLC 
Phosphate : 
acetonitrile 
(60:40v/v) 
(50x4.6mm 
ID, 5µm) 
10. Development and 
validation of stability 
indicating RP-HPLC 
method for simultaneous 
estimation of empagliflozin 
and linagliptin in tablet 
formulation 
0.1% 
perchloric 
acid : 
acetonitrile 
(60:40) 
BDS C18 
column 
(250X4.6mm 
ID, 5µm) 
UV 230 1mL/min 0.43µg/mL [20] 
 
LC - MS/MS 
 Swetha parsha et.a l[21] for the determination of the key impurities in linagliptin pramipexole. The liquid chromatograph was 
carried out in a diode array detector and the control analyst were been performed on Bruker avance 400 MHZ instrument under the 
control of topspin software. Linagliptin key impurity showed the peak at RT 26.4 min and the protenated molecular ion (M
+
 + H) at 
m/z =957.The corresponding molecular formula C51H56N16O4 suggesting that two molecules of linagliptin connected through 
methylene group. 
 
UPLC 
 Nidhi Dubey et.al  [22] studied a simple, precise and accurate isocratic RP-UPLC method for the determination of linagliptin 
in bulk and pharmaceutical formulation. An Isocratic separation has been achieved on an agintent SB –C18 RRHD (50X2.1mm ID, 
1.8µm) column using mobile phase of 0.01M potassium phosphate p
H
 4.0 and acetonitrile (30:70v/v) at a flow rate of 3mL/min. The 
injection volume is 2µL and the detection has been carried out at 292 nm using PDA detector. The method has been validated as per 
ICH guidelines for specificity, linearity, precision, accuracy, robustness and ruggedness. The method is linear in the drug 
concentration range of 2.5-100µg/mL with co-relation coefficient of 0.9998.The proposed method is more sensitive and selective and 
short analysis of time. The LOD and LOQ value represents of 0.25µg/mL and 0.5µg/mL. 
 
Bioanalytical studies 
 Mohammad Al bratty et.al [23] developed a liquid chromatography associated with tandem mass spectrophotometric method 
for the simultaneous estimation of metformin hydrochloride, linagliptin, sidagliptin and vidaliptin from human plasma. The developed 
method was validated as per the ICH guide lines. Chromatographic separations were achieved using chromolith high resolution RP 18 
HPLC column (100x4.6mm, 1.15µm) in an isocratic elution using the mobile phase composed of 0.01M ammonium formate buffer : 
acetonitrile (80:20v/v).The flow rate is 0.4mL/min and was maintained through out the analysis. The detection was performed by 
triple quadrapole MS fitted with ESI probe functioning in the positive ion of MRM mode. Extraction from all drugs from plasma 
followed by acetonitrile crash technique. Alogliptin was used as a internal standard to minimize the error during analysis. The LOD 
where 1.76,1.94,0.17,3.08ng/mL. The developed method is robust and can be applied for monitoring plasma levels of analyzed anti-
diabetic drugs in preclinical and clinical pharmacokinetic studies. 
 On the other hand, Anna guminiczek and Anna bereckle [24] represents a review of analytical methods of the new oral drugs 
for the treatment of type –II diabetes focusing on DPP-4 inhibitors (gliptins) in the human plasma. The review represents the 
analytical procedures in the determination of drugs in the biological samples including HPLC –UV, HPLC –MS, HPTLC, CE-MS & 
electrochemical methods with isotopically labeled internal standards are analysed. 
 
HPTLC 
 Eman I elkimary et.al [25] developed a HPTLC method for the determination of linagliptin, saxagliptin and vidalgliptin in 
the binary mixtures with metformin in pharmaceutical preparations using mobile phase system (Methanol : 0.5% aqueous ammonium 
sulphate 8:2 v/v). Separation was carried out on HPTLC sheet of silica gel 60 F254 and the spots were measured densitometrically at 
225nm for linagliptin and metformin mixture and 208 nm for saxagliptin and metformin mixture. The linear regression analysis data 
were used for the regression line in the range of 0.05-0.5µg/mL for linagliptin. The method was validated and showed good 
performances in terms of linearity LOD, LOQ, precision, accuracy selectivity and specificity. The developed method was 
satisfactorily applied for the analysis of pharmaceutical preparations and proved to be specific and accurate quality control on the sited 
drugs in the dosage forms. 
 
Challenges 
 As discussed earlier, linagliptin belongs to the class of 2 BCS classification which possess high permeability and low 
solubility.Hence the solubility of linagliptin in water is less and it is a problem in selecting the diluents for the analysis. From the 
degradation studies, it was observed that treatment on strong acidic and strong basic will create a difference in the retention time. In 
similar lines spectrophotometric determination, multi dosage forms with complexity in to the presence of multiple entities and 
exceipents which may cause considerable challenge to the analytical chemist in the development of analytical procedure. Due to the 
prevailing lacuna, it is difficult to estimate the individual drugs in the multi component dosage form.  Hence routine spectrometric and 
chemometric methods were been preferred as an alternate resources. 
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CONCLUSION 
 There are a wide range of analytical techniques were available for the analysis of linagliptin in pharmaceutical and biological 
samples. The published data it was revealed that HPLC method was extensively used for the estimation of linagliptin in various 
matrices like plasma and serum. HPLC MS/MS method is also recommended in the determination of linagliptin in biological samples 
because HPLC separation ability with MS sensitivity and selectivity allows the unambiguous identification of linagliptin and its 
metabolites. HPLC with UV detection is applicable in the case of analysis of linagliptin in pharmaceuticals which provide us cost 
effective accurate method when compare with more advance techniques. In the near future, the combinations of linagliptin and 
metformin comninations were been available in the market, various bioanalytical method development and validation has been 
performed in order to study the bioavailablity and bioequivalence of the drug which would help the chemists/analyses to formulate a 
stabilized drug. 
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